Osteolytic Bone Lesions of Multiple Myeloma research, articles, guidelines & medical evidence database search.
Access the latest scientific research and medical evidence related to Osteolytic Bone Lesions of Multiple Myeloma treatment, diagnosis and symptoms, quickly and easily with doctorAsyou.
Designed by medical professionals, for medical professionals, with doctorAsyou you can visualize research in a unique evidence dashboard. You can also export, save and sort results.
Sign up for free for full access.
All Pubmed data courtesy of the U.S. National Library of Medicine. Library last updated 19 December 2020.
Clinical trials databases last updated 1 December 2020 (clinicaltrials.gov) and 1 December 2020 (ictrp)
Sort by
Date
Institutional score
Impact
Patients
List order
Sort
Categories
Studies
111 Unclassified
100 Case Reports
96 Reviews
93 Research
28 Advanced Trials
23 Early Trials
22 Other Trials
1 Meta-Analysis
Guidelines
2 Guidelines
1 Consensuses
Congresses
38 Abstracts
Research
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian Erming, Zhan Fenghuang, Walker Ronald, Rasmussen Erik, Ma Yupo ...
The New England journal of medicine Vol 349(26)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 25 Dec 2003
Research
Magnetic resonance imaging of the spine in multiple myeloma.
Ludwig H, Frühwald F, Tscholakoff D, Rasoul S, Neuhold A ...
Lancet (London, England) Vol 2(8555)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 15 Aug 1987
Research
Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone.
Knowling M A, Harwood A R, Bergsagel D E
Journal of clinical oncology : official journal of the American Societ... Vol 1(4)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 01 Apr 1983
Research
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Dallas S L, Garrett I R, Oyajobi B O, Dallas M R, Boyce B F ...
Blood Vol 93(5)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 01 Mar 1999
Research
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Croucher P I, Shipman C M, Lippitt J, Perry M, Asosingh K ...
Blood Vol 98(13)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 15 Dec 2001
Research
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe Masahiro, Hiura Kenji, Wilde Javier, Moriyama Keiji, Hashimoto Toshihiro ...
Blood Vol 100(6)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 15 Sep 2002
Research
Development of an in vivo model of human multiple myeloma bone disease.
Alsina M, Boyce B, Devlin R D, Anderson J L, Craig F ...
Blood Vol 87(4)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 15 Feb 1996
Research
Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft mode...
Gunn W Grady, Krause Ulf, Lee Narae, Gregory Carl A
Blood Vol 117(5)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 03 Feb 2011
Research
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
Oyajobi Babatunde O, Franchin Giovanni, Williams Paul J, Pulkrabek Donna, Gupta Anjana ...
Blood Vol 102(1)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 01 Jul 2003
Research
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi Daniel J, Oyajobi Babatunde O, Gupta Anjana, McCluskey Brandon, Miao Shichang ...
Blood Vol 120(7)
ReadAdd to library
Add to library
Select a folder
Create a new folder +
Cancel
Date 16 Aug 2012
View
per page
Page
1
2
3
4
5
6
7
8
9
10
Last
